| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 4 | |
| #2 | EPO (European Patent Office) | 3 | |
| #3 | Canada | 2 | |
| #4 | Mexico | 2 | |
| #5 | United States | 2 | |
| #6 | Australia | 1 | |
| #7 | Brazil | 1 | |
| #8 | China | 1 | |
| #9 | India | 1 | |
| #10 | South Africa | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Therapeutic chemical compounds | |
| #3 | Medical preparations |
| # | Name | Total Patents |
|---|---|---|
| #1 | Bhatnagar Rakesh | 15 |
| #2 | Chauhan Vibha | 13 |
| #3 | Gupta Pankaj | 8 |
| #4 | Singh Aparna | 7 |
| #5 | Batra Smriti | 7 |
| #6 | Kumar Praveen | 7 |
| #7 | Ahuja Nidhi | 6 |
| #8 | Kulshreshtha Parul | 2 |
| #9 | Waheed Syed Mohsin | 2 |
| #10 | Mohsin Waheed Sayed | 1 |
| Publication | Filing date | Title |
|---|---|---|
| US2013017201A1 | Bispecific monoclonal antibody capable of cross reacting with lethal factor (lf) and edema factor (ef), and neutralizing edema toxin (et) as well as lethal toxin (lt) of bacillus anthracis | |
| WO2009063507A1 | Dna vaccine against anthrax | |
| AU2002242935A1 | A process for the preparation of a non-toxic anthrax vaccine | |
| EP1442052A1 | High level constitutive production of anthrax protective antigen |